Patients characteristics of 63 obstructive HCM-patients with or without additional CAD and/or HTa, and with or without ventricular arrhythmias
| . | With additional CAD and/or HT (n = 29) . | Without additional CAD and/or HT (n = 34) . | Pb value . | No ventricular arrhythmias (n = 48) . | Ventricular arrhythmias (n = 15) . | Pc value . |
|---|---|---|---|---|---|---|
| Age at symptom onset (years) | 57 ± 15 | 39 ± 15 | <0.001 | 49 ± 13 | 42 ± 19 | 0.16 |
| Age at intervention (years) | 63 ± 11 | 51 ± 13 | <0.001 | 58 ± 13 | 53 ± 13 | 0.24 |
| Female (n) | 15 (52%) | 19 (56%) | 0.74 | 24 (50%) | 10 (67%) | 0.26 |
| BSA (m²) | 1.9 ± 0.2 | 1.9 ± 0.2 | 0.54 | 1.9 ± 0.2 | 1.9 ± 0.2 | 0.22 |
| Familial history of HCM (n) | 6 (21%) | 12 (35%) | 0.20 | 11 (23%) | 7 (47%) | 0.10 |
| Sarcomere gene mutation (n) | 5 (17%) | 19 (56%) | 0.002 | 15 (32%) | 9 (60%) | 0.05 |
| Additional CAD and/or HTa (n) | 25 (52%) | 4 (27%) | 0.09 | |||
| Beta blockers (n) | 27 (93%) | 26 (77%) | 0.09 | 42 (88%) | 11 (73%) | 0.23 |
| Calcium antagonists (n) | 9 (31%) | 12 (35%) | 0.72 | 16 (33%) | 5 (33%) | 1.00 |
| ACE inhibitors/A2 antagonists (n) | 15 (52%) | 1 (3%) | <0.001 | 13 (27%) | 3 (20%) | 0.74 |
| Ventricular arrhythmias (n) | 4 (14%) | 11 (32%) | 0.09 | |||
| Prior cardiac arrest with documented VF (n) | 1 (3%) | 1 (3%) | 1.00 | 0 | 2 (13%) | 0.05 |
| NSVT, n = 59 (n) | 1/26 (4%) | 6/33 (18%) | 0.12 | 0/45 | 7/14 (50%) | <0.001 |
| Unexplained syncope (n) | 2 (7%) | 7 (21%) | 0.16 | 0 | 9 (60%) | <0.001 |
| Premature SCD in the family (n) | 7 (24%) | 6 (18%) | 0.53 | 7 (15%) | 6 (40%) | 0.06 |
| Pathologic blood pressure response during exercise, n = 56, (n) | 5/24 (21%) | 11/32 (34%) | 0.27 | 13/44 (29%) | 3/12 (25%) | 1.00 |
| LV hypertrophy ≥30 mm (n) | 0 | 3 (9%) | 0.24 | 0 | 3 (20%) | 0.01 |
| . | With additional CAD and/or HT (n = 29) . | Without additional CAD and/or HT (n = 34) . | Pb value . | No ventricular arrhythmias (n = 48) . | Ventricular arrhythmias (n = 15) . | Pc value . |
|---|---|---|---|---|---|---|
| Age at symptom onset (years) | 57 ± 15 | 39 ± 15 | <0.001 | 49 ± 13 | 42 ± 19 | 0.16 |
| Age at intervention (years) | 63 ± 11 | 51 ± 13 | <0.001 | 58 ± 13 | 53 ± 13 | 0.24 |
| Female (n) | 15 (52%) | 19 (56%) | 0.74 | 24 (50%) | 10 (67%) | 0.26 |
| BSA (m²) | 1.9 ± 0.2 | 1.9 ± 0.2 | 0.54 | 1.9 ± 0.2 | 1.9 ± 0.2 | 0.22 |
| Familial history of HCM (n) | 6 (21%) | 12 (35%) | 0.20 | 11 (23%) | 7 (47%) | 0.10 |
| Sarcomere gene mutation (n) | 5 (17%) | 19 (56%) | 0.002 | 15 (32%) | 9 (60%) | 0.05 |
| Additional CAD and/or HTa (n) | 25 (52%) | 4 (27%) | 0.09 | |||
| Beta blockers (n) | 27 (93%) | 26 (77%) | 0.09 | 42 (88%) | 11 (73%) | 0.23 |
| Calcium antagonists (n) | 9 (31%) | 12 (35%) | 0.72 | 16 (33%) | 5 (33%) | 1.00 |
| ACE inhibitors/A2 antagonists (n) | 15 (52%) | 1 (3%) | <0.001 | 13 (27%) | 3 (20%) | 0.74 |
| Ventricular arrhythmias (n) | 4 (14%) | 11 (32%) | 0.09 | |||
| Prior cardiac arrest with documented VF (n) | 1 (3%) | 1 (3%) | 1.00 | 0 | 2 (13%) | 0.05 |
| NSVT, n = 59 (n) | 1/26 (4%) | 6/33 (18%) | 0.12 | 0/45 | 7/14 (50%) | <0.001 |
| Unexplained syncope (n) | 2 (7%) | 7 (21%) | 0.16 | 0 | 9 (60%) | <0.001 |
| Premature SCD in the family (n) | 7 (24%) | 6 (18%) | 0.53 | 7 (15%) | 6 (40%) | 0.06 |
| Pathologic blood pressure response during exercise, n = 56, (n) | 5/24 (21%) | 11/32 (34%) | 0.27 | 13/44 (29%) | 3/12 (25%) | 1.00 |
| LV hypertrophy ≥30 mm (n) | 0 | 3 (9%) | 0.24 | 0 | 3 (20%) | 0.01 |
Values are mean ± SD and n (%) when appropriate.
HCM, hypertrophic cardiomyopathy; CAD, coronary artery disease; HT, hypertension; BSA, body surface area; ACE inhibitors, angiotensin-converting enzyme inhibitors; A2 antagonists, angiotensin 2 antagonists; VF, ventricular fibrillation; NSVT, non-sustained ventricular tachycardia; SCD, sudden cardiac death; LV, left ventricle.
aTreatment for HT.
bComparisons between HCM-patients with or without additional CAD and/or HT.
cComparisons between HCM-patients with or without ventricular arrhythmias.
Patients characteristics of 63 obstructive HCM-patients with or without additional CAD and/or HTa, and with or without ventricular arrhythmias
| . | With additional CAD and/or HT (n = 29) . | Without additional CAD and/or HT (n = 34) . | Pb value . | No ventricular arrhythmias (n = 48) . | Ventricular arrhythmias (n = 15) . | Pc value . |
|---|---|---|---|---|---|---|
| Age at symptom onset (years) | 57 ± 15 | 39 ± 15 | <0.001 | 49 ± 13 | 42 ± 19 | 0.16 |
| Age at intervention (years) | 63 ± 11 | 51 ± 13 | <0.001 | 58 ± 13 | 53 ± 13 | 0.24 |
| Female (n) | 15 (52%) | 19 (56%) | 0.74 | 24 (50%) | 10 (67%) | 0.26 |
| BSA (m²) | 1.9 ± 0.2 | 1.9 ± 0.2 | 0.54 | 1.9 ± 0.2 | 1.9 ± 0.2 | 0.22 |
| Familial history of HCM (n) | 6 (21%) | 12 (35%) | 0.20 | 11 (23%) | 7 (47%) | 0.10 |
| Sarcomere gene mutation (n) | 5 (17%) | 19 (56%) | 0.002 | 15 (32%) | 9 (60%) | 0.05 |
| Additional CAD and/or HTa (n) | 25 (52%) | 4 (27%) | 0.09 | |||
| Beta blockers (n) | 27 (93%) | 26 (77%) | 0.09 | 42 (88%) | 11 (73%) | 0.23 |
| Calcium antagonists (n) | 9 (31%) | 12 (35%) | 0.72 | 16 (33%) | 5 (33%) | 1.00 |
| ACE inhibitors/A2 antagonists (n) | 15 (52%) | 1 (3%) | <0.001 | 13 (27%) | 3 (20%) | 0.74 |
| Ventricular arrhythmias (n) | 4 (14%) | 11 (32%) | 0.09 | |||
| Prior cardiac arrest with documented VF (n) | 1 (3%) | 1 (3%) | 1.00 | 0 | 2 (13%) | 0.05 |
| NSVT, n = 59 (n) | 1/26 (4%) | 6/33 (18%) | 0.12 | 0/45 | 7/14 (50%) | <0.001 |
| Unexplained syncope (n) | 2 (7%) | 7 (21%) | 0.16 | 0 | 9 (60%) | <0.001 |
| Premature SCD in the family (n) | 7 (24%) | 6 (18%) | 0.53 | 7 (15%) | 6 (40%) | 0.06 |
| Pathologic blood pressure response during exercise, n = 56, (n) | 5/24 (21%) | 11/32 (34%) | 0.27 | 13/44 (29%) | 3/12 (25%) | 1.00 |
| LV hypertrophy ≥30 mm (n) | 0 | 3 (9%) | 0.24 | 0 | 3 (20%) | 0.01 |
| . | With additional CAD and/or HT (n = 29) . | Without additional CAD and/or HT (n = 34) . | Pb value . | No ventricular arrhythmias (n = 48) . | Ventricular arrhythmias (n = 15) . | Pc value . |
|---|---|---|---|---|---|---|
| Age at symptom onset (years) | 57 ± 15 | 39 ± 15 | <0.001 | 49 ± 13 | 42 ± 19 | 0.16 |
| Age at intervention (years) | 63 ± 11 | 51 ± 13 | <0.001 | 58 ± 13 | 53 ± 13 | 0.24 |
| Female (n) | 15 (52%) | 19 (56%) | 0.74 | 24 (50%) | 10 (67%) | 0.26 |
| BSA (m²) | 1.9 ± 0.2 | 1.9 ± 0.2 | 0.54 | 1.9 ± 0.2 | 1.9 ± 0.2 | 0.22 |
| Familial history of HCM (n) | 6 (21%) | 12 (35%) | 0.20 | 11 (23%) | 7 (47%) | 0.10 |
| Sarcomere gene mutation (n) | 5 (17%) | 19 (56%) | 0.002 | 15 (32%) | 9 (60%) | 0.05 |
| Additional CAD and/or HTa (n) | 25 (52%) | 4 (27%) | 0.09 | |||
| Beta blockers (n) | 27 (93%) | 26 (77%) | 0.09 | 42 (88%) | 11 (73%) | 0.23 |
| Calcium antagonists (n) | 9 (31%) | 12 (35%) | 0.72 | 16 (33%) | 5 (33%) | 1.00 |
| ACE inhibitors/A2 antagonists (n) | 15 (52%) | 1 (3%) | <0.001 | 13 (27%) | 3 (20%) | 0.74 |
| Ventricular arrhythmias (n) | 4 (14%) | 11 (32%) | 0.09 | |||
| Prior cardiac arrest with documented VF (n) | 1 (3%) | 1 (3%) | 1.00 | 0 | 2 (13%) | 0.05 |
| NSVT, n = 59 (n) | 1/26 (4%) | 6/33 (18%) | 0.12 | 0/45 | 7/14 (50%) | <0.001 |
| Unexplained syncope (n) | 2 (7%) | 7 (21%) | 0.16 | 0 | 9 (60%) | <0.001 |
| Premature SCD in the family (n) | 7 (24%) | 6 (18%) | 0.53 | 7 (15%) | 6 (40%) | 0.06 |
| Pathologic blood pressure response during exercise, n = 56, (n) | 5/24 (21%) | 11/32 (34%) | 0.27 | 13/44 (29%) | 3/12 (25%) | 1.00 |
| LV hypertrophy ≥30 mm (n) | 0 | 3 (9%) | 0.24 | 0 | 3 (20%) | 0.01 |
Values are mean ± SD and n (%) when appropriate.
HCM, hypertrophic cardiomyopathy; CAD, coronary artery disease; HT, hypertension; BSA, body surface area; ACE inhibitors, angiotensin-converting enzyme inhibitors; A2 antagonists, angiotensin 2 antagonists; VF, ventricular fibrillation; NSVT, non-sustained ventricular tachycardia; SCD, sudden cardiac death; LV, left ventricle.
aTreatment for HT.
bComparisons between HCM-patients with or without additional CAD and/or HT.
cComparisons between HCM-patients with or without ventricular arrhythmias.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
